The mitochondrial disease therapy developer's latest round was co-led by Novo Ventures and backed by returning investor Lundbeckfonden Ventures.

Koch Industries took part in a series B round for the identity management platform developer that increased its total funding to $105m since its launch earlier this year.

SBI was among the participants in the financial management tool developer's seriies B round, which will fund product development and US expansion.

Novo returned to reinvest in the neuromuscular disorder therapy developer in a round that will fund the progress of its lead candidate through a phase 1 clinical trial.

The digital medicine provider has closed a round led by SoftBank Vision Fund 2 that also featured Novartis, taking its total funding to at least $214m.

The database technology provider formerly known as MemSQL increased its overall financing to $238m in a round featuring GV, REV and Dell Technologies Capital.

The rocket launcher developer has received $90.8m in an Airbus Ventures-backed round as it prepares for a first commercial launch in 2022.

Alexandria Venture Investments has helped RNA drug developer Remix Therapeutics launch with seed and series A funding.

Citi Ventures participated in the first non-crowdfunded equity round to be disclosed by the kids' finance management app developer.

Amgen is a shareholder of Vigil Neuroscience, which is developing microglia-based treatments for neurodegenerative diseases.